百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

交易中 01-13 12:16:02 EST

346.47

+12.48

+3.74%

最高347.75	最低335.29	成交量16.77万
今开339.16	昨收333.99	日振幅3.73%
总市值412.30亿	流通市值262.08亿	总股本1.19亿
成交额5,736万	换手率0.22%	流通股本7,564万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":346.47,"timestamp":1768324562025,"preClose":333.99,"halted":0,"volume":167674,"delay":0,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"交易中","change":12.48,"latestTime":"01-13 12:16:02 EST","open":339.16,"high":347.75,"low":335.29,"amount":57364218.0787,"amplitude":0.037307,"askPrice":346.77,"askSize":6,"bidPrice":346.14,"bidSize":26,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1768338000000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":333.99,"preHourTrading":{"tag":"盘前","latestPrice":333.99,"preClose":333.99,"latestTime":"08:21 EST","volume":54818,"amount":18308810.73224,"timestamp":1768310472190},"postHourTrading":{"tag":"盘后","latestPrice":333.99,"preClose":333.99,"latestTime":"19:39 EST","volume":994,"amount":331985.98,"timestamp":1768264740982},"volumeRatio":0.806681,"impliedVol":0.3803,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2601787308","title":"百济神州(06160)授出合共5.33万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601787308?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1719994722.HKD","BK1500","688235","BK0239","06160","LU1969619763.USD","BK4585","BK1588","BK4139","LU0588546209.SGD","ONC","BK1583","LU0307460666.USD","BK1161","LU2328871848.SGD","LU1251922891.USD","LU1303224171.USD","LU1770034418.SGD","BK4526"],"gpt_icon":0},{"id":"1170001608","title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170001608?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ONC","LU1303224171.USD","LU2328871848.SGD","BK1583","LU1719994722.HKD","06160","LU1969619763.USD","BK0239","BK1161","LU1251922891.USD","BK1500","BK4139","BK4526","LU0307460666.USD","LU0588546209.SGD","BK1588","688235","LU1770034418.SGD"],"gpt_icon":0},{"id":"2601917854","title":"重磅，百济神州又一款1类新药迎来新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917854","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601917854?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:01","pubTimestamp":1767657678,"startTime":"0","endTime":"0","summary":"特应性皮炎，这一慢性、复发性、炎症性皮肤病，近年来在全球范围内发病率持续上升，给患者的生活质量带来了严重影响。BGB-45035是百济神州开发的一款IRAK4 CDAC，正被研究用于治疗各类自身免疫性疾病。据报道，该药物具有潜力诱导更深、更快的IRAK4降解，并且细胞因子抑制作用更强，是百济神州在自有CDAC平台上研发的第二款靶向降解剂。IRAK4作为先天免疫关键靶点，近年来受到多家药企关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4585","BK4139","06160"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4585","01167","06160","02509","CXO","BMS","01541","00013","BK4139","BK4526","01801"],"gpt_icon":0},{"id":"2601854164","title":"百济神州盘中异动 早盘急速上涨5.44%报327.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854164?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:31","pubTimestamp":1767623486,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时31分，百济神州股票出现波动，股价急速上涨5.44%。截至发稿，该股报327.95美元/股，成交量2.6425万股，换手率0.02%，振幅2.00%。百济神州股票所在的生物技术行业中，整体跌幅为0.32%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC","BK4585"],"gpt_icon":0},{"id":"2601854118","title":"百济神州BG - C0902启动Ⅰ期临床 适应症为晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854118","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854118?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:30","pubTimestamp":1767609000,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，广州百济神州生物制药有限公司的一项探索靶向 EGFR×MET 的抗体偶联药物 BG - C0902 单药治疗和与其他治疗药物联合用药治疗晚期实体瘤患者的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1a/1b 期研究已启动。BG - C0902 为生物制品，适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2211817866.USD","BG","LU0742534661.SGD","BK4139","BK4189","LU0471298694.HKD","LU0471298777.SGD","LU2360106947.USD","ONC","BK4588","LU0385154629.USD","LU0048573561.USD","LU0251131958.USD","LU0251142724.SGD","BK4526","BK4585"],"gpt_icon":0},{"id":"2601800005","title":"百济神州BCL-2抑制剂“索托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601800005?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LU0307460666.USD","688235","BK1161","LU2328871848.SGD","BK0239","BK4139","LU1303224171.USD","LU1969619763.USD","BK1583","06160","LU1719994722.HKD","BK1500","LU0588546209.SGD","ONC","BK4526","LU1251922891.USD","LU1770034418.SGD","BK1588"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477930?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274308.USD","LU2488822045.USD","LU0561508036.HKD","LU0634319403.HKD","LU1794554557.SGD","LU0348784397.USD","01801","LU0417516738.SGD","ONC","01276","09926","06978","LU1961090484.USD","BK1161","LU0348827113.USD","LU0348767384.USD","LU0348783233.USD","LU0348735423.USD","LU2399975544.HKD","LU2778985437.USD","IE00B543WZ88.USD","01877","LU0348766576.USD","LU0348825331.USD","LU0417516902.SGD","IE00BPRC5H50.USD","BK1574","LU2476274720.SGD","LU0417516571.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0540923850.HKD"],"gpt_icon":0},{"id":"2594405085","title":"21专访丨高特佳投资副总经理于建林：锚定下一代疗法 创新药行业走向价值深化","url":"https://stock-news.laohu8.com/highlight/detail?id=2594405085","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594405085?lang=zh_cn&edition=full","pubTime":"2025-12-24 07:00","pubTimestamp":1766530800,"startTime":"0","endTime":"0","summary":"高特佳投资集团副总经理于建林在接受21世纪经济报道记者专访时也指出，中国创新药行业已迈入高质量发展新阶段。于建林进一步表示。2026年港股依旧是中国未盈利创新药企业上市的核心阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224070019a6c78236&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526","BK4585"],"gpt_icon":0},{"id":"2592959471","title":"双总裁时代的百济神州 还有哪些故事可讲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592959471","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592959471?lang=zh_cn&edition=full","pubTime":"2025-12-19 23:31","pubTimestamp":1766158317,"startTime":"0","endTime":"0","summary":"12月19日，百济神州迎来新的人事调整。百济神州发布公告称，公司董事会同意聘任全球研发负责人汪来博士担任百济神州总裁，全球研发负责人。聘任生效后，汪来将担任百济神州总裁，全球研发负责人职务，负责管理百济神州研发、业务拓展以及业务联盟关系管理等职能。此外，百济神州方面还透露，吴晓滨仍然担任百济神州总裁、首席运营官COO，与汪来并列为双总裁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193597095415.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193597095415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","BK1588","688235","LU2328871848.SGD","BK4585","LU1770034418.SGD","ONC","BK4139","BK0239","LU0307460666.USD","BK1500","LU1251922891.USD","06160","LU1969619763.USD","LU1303224171.USD","BK1583","BK1161","LU1719994722.HKD","LU0588546209.SGD"],"gpt_icon":0},{"id":"2591376935","title":"TIGIT抗体再折戟：胃癌三期失败，免疫治疗前路何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591376935","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591376935?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:03","pubTimestamp":1765839790,"startTime":"0","endTime":"0","summary":"2025年12月12日，吉利德与Arcus Biosciences联合宣布，其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折，也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。PD-1/TIGIT双抗可以同时阻断这两条免疫逃逸通路，恢复T细胞和NK细胞的活性，产生更强的抗肿瘤免疫反应 。PD-1/TIGIT双抗若能在临床试验中取得成功，将有望填补肿瘤免疫治疗领域的空白，满足未被满足的临床需求，市场潜力巨大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216070651a6a6b74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1303224171.USD","LU2328871848.SGD","LU1719994722.HKD","BK1500","06160","BK1583","LU1969619763.USD","LU1770034418.SGD","BK1161","ONC","BK1588","LU1251922891.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。　　阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。　　把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","LU0634319403.HKD","688235","BK4139","LU0348766576.USD","LU1969619763.USD","LU2476274308.USD","LU0561508036.HKD","LU0348827113.USD","BK1161","ONC","IE00B5MMRT66.SGD","LU0588546209.SGD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348767384.USD","06160","LU2476274720.SGD","09926","LU2488822045.USD","LU1770034418.SGD","LU2778985437.USD","LU0417516902.SGD","LU0307460666.USD","LU2399975544.HKD","LU1303224171.USD","IE00B543WZ88.USD","LU1720050803.USD","LU0348783233.USD","BK1500","BK1583","520880","LU1794554557.SGD","BK4585","LU1719994722.HKD","BK1574","LU0540923850.HKD","LU0417516738.SGD","LU2328871848.SGD","LU0348784397.USD","LU0348825331.USD","LU0348735423.USD","BK0239","BK1588","LU1251922891.USD","LU0417516571.SGD"],"gpt_icon":0},{"id":"2590348233","title":"中信证券：医保谈判成功率创近年新高，关注创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348233","media":"瑞财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348233?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:57","pubTimestamp":1765263437,"startTime":"0","endTime":"0","summary":"瑞财经 严明会近日，中信证券指出，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。在基本医保目录上，最终114个成功纳入，其中包含50个1类创新药，成功率为88%，谈判成功率创近7年新高。与此同时，首版商保目录发布，共纳入19款产品，包含5款CAR-T产品。中信证券认为，伴随着国家对创新药持续的政策倾斜和鼓励支持，医保和商保的双轨并行，有望带动支付多元化，创新药企的回报有望逐步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4585","02359","ONC","06160","BK4139"],"gpt_icon":0},{"id":"2590348255","title":"药价登记，出海新支点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348255","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348255?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:58","pubTimestamp":1765252739,"startTime":"0","endTime":"0","summary":"本土龙头企业如恒瑞医药、百济神州等持续投入高额研发费用，其中恒瑞医药已在中国获批上市23款1类新分子实体创新药，覆盖肿瘤、自身免疫等领域。从早期的原料药出口，到现在的创新药License-out，2025年上半年国产创新药对外授权交易总金额已接近660亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK4139","BK4585","ONC","BK4526","06160"],"gpt_icon":0},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","02161","02196","LU0154236417.USD","IE00BKVL7J92.USD","BK4599","06160","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","BK4022","BK4585","BK4230","02171","BK4007","LU1093756168.USD","01228","BK4588","BK4532"],"gpt_icon":0},{"id":"2589387525","title":"百济神州两款药品进入2025年商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589387525","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589387525?lang=zh_cn&edition=full","pubTime":"2025-12-07 13:56","pubTimestamp":1765086982,"startTime":"0","endTime":"0","summary":"【百济神州两款药品进入2025年商保创新药目录】12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中，百济神州有两款药品成功纳入，包括达妥昔单抗β注射液以及注射用泽尼达妥单抗。百济神州也是唯一一家两款产品进入商保创新药目录的创新药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584561139.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584561139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688235","ONC","LU1969619763.USD","LU1719994722.HKD","BK4526","LU0307460666.USD","LU1303224171.USD","06160","06978","BK1500","BK1574","LU1770034418.SGD","BK4585","159992","BK1588","LU1251922891.USD","BK4139","LU0588546209.SGD","BK1161","LU2328871848.SGD","BK0239","BK1583"],"gpt_icon":0},{"id":"2588002521","title":"百济神州(06160)授出合共2.13万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002521?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2328871848.SGD","LU1303224171.USD","BK4139","BK4585","LU1719994722.HKD","BK0239","ONC","LU0307460666.USD","BK4526","LU1969619763.USD","BK1588","BK1583","BK1500","LU1770034418.SGD","LU0588546209.SGD","06160","LU1251922891.USD","688235"],"gpt_icon":0},{"id":"2585015452","title":"近一个月内，我武生物等多家国内药企研发项目终止！","url":"https://stock-news.laohu8.com/highlight/detail?id=2585015452","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585015452?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:42","pubTimestamp":1763970164,"startTime":"0","endTime":"0","summary":"如近一个月内，多家国内药企的研发项目就已终止。11月14日消息，我武生物公告称，公司管理层决定终止烟曲霉点刺液研发项目，不再开展后续临床试验。该药物用于辅助诊断因烟曲霉致敏引起的I型变态反应性疾病。11月12日，同润生物宣布启动清算解散。11月3日，派格生物发布公告称，已于10月28日申请自愿解散非全资附属公司上海迈迹。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","BK4585","ONC","06160"],"gpt_icon":0},{"id":"2585090452","title":"科创生物医药ETF涨1.42%，成交额737.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585090452","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585090452?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:05","pubTimestamp":1763967900,"startTime":"0","endTime":"0","summary":"11月24日，鹏华上证科创板生物医药ETF收盘涨1.42%，成交额737.09万元。该基金成立于2025年3月12日，全称为鹏华上证科创板生物医药交易型开放式指数证券投资基金，管理费率每年0.50%，托管费率每年0.10%，业绩比较基准为上证科创板生物医药指数收益率。规模上，截至11月21日，其最新份额为2.02亿份，规模2.28亿元；流动性方面，截至11月24日，近20个交易日累计成交金额3.08亿元，日均成交金额1542.47万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","06160","ONC","BK4526"],"gpt_icon":0},{"id":"2585345202","title":"趋势研判！2025年中国BTK抑制剂行业发展历程、产业链、市场规模、竞争格局及发展趋势分析：市场呈现出巨大增长潜力，未来市场竞争愈加激烈[图]","url":"https://stock-news.laohu8.com/highlight/detail?id=2585345202","media":"智研咨询","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585345202?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:12","pubTimestamp":1763946720,"startTime":"0","endTime":"0","summary":"预计2025年全球BTK抑制剂市场规模将达到130亿美元，中国BTK抑制剂市场规模增长至49亿元。目前，我国已批准5种BTK抑制剂用于临床治疗，它们分别为伊布替尼、泽布替尼、阿卡替尼、奥布替尼、匹妥布替尼。随着对BTK抑制剂在疾病发生发展中作用的深入理解和技术的不断进步，我国BTK抑制剂行业正处于快速发展和变革的时期，市场呈现出巨大增长潜力。国内多家药企正在积极研发新一代BTK抑制剂，未来市场竞争将更加激烈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCR","BK4585","BK4139","ONC","06160","BK4526"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":0.0468},{"period":"3month","weight":0.0407},{"period":"6month","weight":0.1964},{"period":"1year","weight":0.89},{"period":"ytd","weight":0.0993}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.081606},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.147208},{"month":8,"riseRate":0.6,"avgChangeRate":0.034201},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}